

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/209264 A1

(43) International Publication Date
10 October 2024 (10.10.2024)

(51) International Patent Classification:

A61K 8/04 (2006.01) A61K 8/49 (2006.01)
A61K 8/26 (2006.01) A61K 8/58 (2006.01)
A61K 8/37 (2006.01) A61Q 15/00 (2006.01)

(21) International Application Number:

PCT/IB2024/000107

(22) International Filing Date:

11 March 2024 (11.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2305054.5 05 April 2023 (05.04.2023) GB

(72) Inventor; and

(71) Applicant: DAVIES, Jonathan [GB/GB]; Unit 1A, The Southwest Centre, 4 Archer Road, Sheffield S8 0JR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: ANTIPERSPIRANT AND DEODORANT COMPOSITION

(57) Abstract: The present invention relates to antiperspirant and deodorant compositions for correction of body odour, and more particularly relates to antiperspirant and deodorant compositions for human hygiene. The disclosed anti-perspirant and deodorant composition comprises isobutane, propane, butane, cyclopentasiloxane, caprylic/capric triglyceride, stearylalkonium hectorite, propylene carbonate, c12-15 alkyl benzoate, parfum, silver lactate, lactic acid, aqua, zein starch, menthyl ethylamido oxalate, argania spinosa kernel oil. Furthermore, the active antimicrobial silver ingredient is dermatologically tested and is capable of diminishing odor-causing bacteria in addition to prevention of irritation and itching.



WO 2024/209264 A1

INTERNATIONAL PATENT APPLICATION**SPECIFICATION****TITLE OF THE INVENTION**

Antiperspirant and Deodorant Composition

TECHNICAL FIELD OF THE INVENTION

1 The present invention relates to antiperspirant and deodorant compositions for correction of
2 body odour, and more particularly relates to antiperspirant and deodorant compositions for
3 human hygiene.

BACKGROUND OF THE INVENTION

4 Deodorants and antiperspirants are personal care products made to reduce or get rid of
5 perspiration and body odour. Antiperspirants operate by blocking sweat glands to limit
6 perspiration production, whereas deodorants hide or neutralise the odour caused by bacteria
7 that live on sweat.

8 Typically, deodorants and antiperspirants combine active chemicals with other elements to
9 provide the desired benefits. Antimicrobial compounds like triclosan or phenoxyethanol, which
10 destroy the germs that produce odour, are commonly found as the active components in
11 deodorants. For added benefits, other substances like moisturisers and fragrances may also be
12 used.

13 On the other hand, antiperspirants contain active chemicals such as aluminium salts that limit
14 perspiration production by producing a blockage in the sweat ducts. For added benefits, other
15 substances including skin conditioners and fragrances may also be used. In order to appeal to
16 consumers, deodorants and antiperspirants are frequently created with aromas that are viewed

17 reflecting different aroma. To further underline their efficacy, they may also be advertised with
18 different phrases.

19 Some customers prefer deodorants that are natural or free of aluminium and that use chemicals
20 like baking soda, cornstarch, or essential oils to lessen odour and perspiration. These products
21 might be promoted as healthier or more environmentally friendly substitutes for more
22 conventional deodorants and antiperspirants.

23 Human intimate hygiene specific antiperspirant and deodorant products are growing in
24 popularity as more people look for solutions to problems like odour, sweating, and chafing in
25 sensitive areas. Antiperspirants for intimate areas frequently have active ingredients such
26 as aluminium chloride, which limit perspiration formation by blocking sweat
27 glands. Deodorants made for private regions frequently include antimicrobial ingredients like
28 triclosan or chlorhexidine, which eliminate odor-causing microorganisms. Aloe vera and witch
29 hazel are examples of additional ingredients that may be used to give the skin additional
30 advantages like relaxing and moisturising effect.

31 There are several drawbacks related to using antiperspirant and deodorant compositions in
32 intimate areas for humans. The skin in the intimate area is sensitive and can be easily irritated
33 by certain ingredients found in antiperspirants and deodorants, such as alcohol, fragrances, and
34 certain antimicrobial agents. This can cause redness, itching, and discomfort.

35 Antimicrobial agents found in deodorants and antiperspirants can disrupt the natural bacterial
36 flora in the intimate area, potentially leading to an overgrowth of harmful bacteria and
37 increased risk of infection. There is some concern that certain ingredients in antiperspirants
38 and deodorants, such as aluminum salts, may be absorbed by the body and contribute to health
39 problems such as Alzheimer's disease. However, more research is needed to confirm these
40 claims. Antiperspirants and deodorants may not be as effective in the intimate area, as the skin

41 is often damp and subject to friction, which can reduce the product's ability to adhere to the
42 skin and provide protection.

43 There are very few products in the market that are specifically formulated for use in intimate
44 areas and contain gentle, pH-balanced ingredients that won't irritate the skin. Fragrance-free
45 products may be especially helpful in avoiding irritation, however, such anti-perspirant and
46 deodorant compositions still have their drawbacks. It is key to note that whilst existing
47 antiperspirant deodorants can be sprayed onto the intimate area by choice of the user, this type
48 of usage comes with the imposed risks that are mentioned above, thus they cannot be
49 recommended or marketed for intimate usage as they have not been specially formulated and
50 tested as such, whereas the disclosed invention has been formulated and tested to meet the
51 satisfactory requirements of both of these criteria.

52 In view of this, various solutions have been proposed, none combine the characteristics of the
53 present invention. Thus, there is a need for an anti-perspirant and deodorant composition that
54 is safe to use at intimate areas and can diminish the odour causing bacteria.

SUMMARY OF THE INVENTION

55 Embodiments of the invention solve the above-mentioned problems by providing an anti-
56 perspirant and deodorant composition. The disclosed anti-perspirant and deodorant
57 composition comprises isobutane, propane, butane, cyclopentasiloxane, caprylic/capric
58 triglyceride, stearylalkonium hectorite, propylene carbonate, c12-15 alkyl benzoate, parfum,
59 silver lactate, lactic acid, aqua, zea mays starch, menthyl ethylamido oxalate, argania spinosa
60 kernel oil. Furthermore, the active antimicrobial silver ingredient is dermatologically tested
61 and is capable of diminishing odor-causing bacteria in addition to prevention of irritation &
62 itching.

63 This summary is provided merely for purposes of summarizing some example embodiments,
64 so as to provide a basic understanding of some aspects of the subject matter described herein.
65 Accordingly, it will be appreciated that the above-described features are merely examples and
66 should not be construed to narrow the scope or spirit of the subject matter described herein in
67 any way. Other aspects, and advantages of the subject matter described herein will become
68 apparent from the following detailed description, and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Drawings are not required as the subject matter of the present invention is related to a
composition.

DETAILED DESCRIPTION OF THE INVENTION

69 The following detailed description are intended to describe aspects of the invention in sufficient
70 detail to enable those skilled in the art to practice the invention. Other embodiments can be

71 utilized, and changes can be made without departing from the scope of the invention. The
72 following detailed description is, therefore, not to be taken in a limiting sense. The scope of
73 the invention is defined only by the appended claims, along with the full scope of equivalents
74 to which such claims are entitled.

75 In this description, references to “one embodiment,” “an embodiment,” or “embodiments”
76 mean that the feature or features being referred to are included in at least one embodiment of
77 the technology. Separate references to “one embodiment,” “an embodiment,” or
78 “embodiments” in this description do not necessarily refer to the same embodiment and are
79 also not mutually exclusive unless so stated and/or except as will be readily apparent to those
80 skilled in the art from the description. For example, a feature, structure, act, etc. described in
81 one embodiment may also be included in other embodiments but is not necessarily included.
82 Thus, embodiments of the invention can include a variety of combinations and/or integrations
83 of the embodiments described herein.

84 The present invention discloses an anti-perspirant and deodorant composition comprises
85 isobutane, propane, butane, cyclopentasiloxane, caprylic/capric triglyceride, stearylalkonium
86 hectorite, propylene carbonate, c12-15 alkyl benzoate, parfum, silver lactate, lactic acid, aqua,
87 zea mays starch, menthyl ethylamido oxalate, argania spinosa kernel oil. Furthermore, the
88 active antimicrobial silver ingredient is dermatologically tested and is capable of diminishing
89 odor-causing bacteria in addition to preventing irritation and itching.

90 In one embodiment, the present invention comprises propellant made from well selected
91 mixtures of isobutane, butane, and propane that has been readily purified and deodorised using
92 various hydrogenation and separation procedures. Its carefully balanced composition ensures
93 the appropriate gas pressure for each application. These products are especially designed to

94 function as expansion gases in polymeric materials and as propellants in aerosols for packaged
95 products for a variety of applications.

96 In the same embodiment, the composition further comprises Cyclopentasiloxane as a hair or
97 skin conditioning agent. Cyclopentasiloxane is a silicone that is commonly found in cosmetics.
98 It is frequently present in lubricants, sealants, medical implants, and windscreen coatings. It is
99 water-thin, odourless, colorless, and non-greasy. It does not penetrate the skin. Instead, it
100 quickly evaporates away from it. Its property to dry fast makes it a valuable ingredient for
101 cosmetics like antiperspirants and hair sprays.

102 In the same embodiment, the composition further comprises Bentone Gel® GTCC V that
103 further includes Capric Triglyceride, Stearalkonium Hectorite, and Propylene Carbonate.
104 Specifically, Capric Triglyceride acts as a fragrance, perfuming and skin condition agent
105 whereas Stearalkonium Hectorite acts as a gel forming and viscosity controlling agent and
106 Propylene Carbonate acts as solvent viscosity controlling agent.

107 In the same embodiment, the composition further comprises C12-15 alkyl benzoate that
108 functions as an emollient (skin-softening, moisture-sealing), texture-enhancing and dispersing
109 agent. In addition, C12-15 alkyl benzoate also has antimicrobial properties.

110 In the same embodiment, the composition further comprises parfum that has deodorant,
111 masking, and perfuming function.

112 In the same embodiment, the composition further comprises silver lactate, lactic acid and aqua
113 in which silver lactate acts as a deodorant, lactic acid has buffering humectant and skin
114 conditioning function and aqua is used as a solvent.

115 In the same embodiment, the composition further comprises Zea Mays Starch and Aqua in
116 which Zea Mays Starch has abrasive absorbent anticaking and viscosity controlling properties

117 whereas aqua is use as solvent. One of the major functions of Zea Mays Starch is to make
118 deodorant feel dry (rather than wet or slippery) as its applied.

119 In the same embodiment, the composition further comprises Menthyl Ethylamido Oxalate for
120 skin conditioning.

121 In the same embodiment, the composition further comprises Argania Spinosa Kernel Oil that
122 has emollient and skin conditioning properties.

123 In a preferred embodiment, an anti-perspirant and deodorant composition comprising:
124 propellants that further includes 65.4356% w/w w/w of isobutane, 16.4000% w/w of propane,
125 and 0.1640% w/w of butane; 8.2000% w/w of cyclopentasiloxane that has hair conditioning,
126 skin conditioning, emollient, and solvent properties; 3.4960% w/w of caprylic/capric
127 triglyceride that has fragrance, skin conditioning, perfuming properties; 0.2920% w/w of
128 stearalkonium hectorite that has gel forming and viscosity controlling properties; 0.2120%
129 w/w of propylene carbonate that has solvent and viscosity controlling properties; 2.0000%
130 w/w of c12-15 alkyl benzoate that has antimicrobial, emollient and skin conditioning
131 properties; 0.2000% w/w of parfum that has deodorant, masking and perfuming properties;
132 0.0023% w/w of silver lactate that has deodorant properties; 0.0023% w/w of lactic acid that
133 has buffering, humectant, and skin conditioning properties; 0.4955% w/w of aqua that act as
134 solvent; 1.7400% w/w of zea mays starch that has abrasive, absorbent, anticaking, skin
135 protecting, and viscosity controlling properties, and 0.2600 of aqua that acts as solvent;
136 0.1000% w/w of menthyl ethylamido oxalate that has skin conditioning properties; and
137 1.0000% w/w of argania spinosa kernel oil that further has emollient and skin conditioning
138 properties.

139 Although the description above contains many specifics, these should not be construed as
140 limiting the scope of the embodiments but as merely providing illustrations of some of several
141 embodiments.

142 All percentages and ratios are calculated by weight unless otherwise indicated. All percentages
143 and ratios are calculated based on the total composition unless otherwise indicated.

144 It should be understood that every maximum numerical limitation given throughout this
145 specification includes every lower numerical limitation, as if such lower numerical limitations
146 were expressly written herein. Every minimum numerical limitation given throughout this
147 specification will include every higher numerical limitation, as if such higher numerical
148 limitations were expressly written herein. Every numerical range given throughout this
149 specification will include every narrower numerical range that falls within such broader
150 numerical range, as if such narrower numerical ranges were all expressly written herein.

151 The dimensions and values disclosed herein are not to be understood as being strictly limited
152 to the exact numerical values recited. Instead, unless otherwise specified, each such dimension
153 is intended to mean both the recited value and a functionally equivalent range surrounding that
154 value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm”.

155 Every document cited herein, including any cross referenced or related patent or application
156 and any patent application or patent to which this application claims priority or benefit thereof,
157 is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise
158 limited. The citation of any document is not an admission that it is prior art with respect to any
159 invention disclosed or claimed herein or that it alone, or in any combination with any other
160 reference or references, teaches, suggests or discloses any such invention. Further, to the extent
161 that any meaning or definition of a term in this document conflicts with any meaning or

162 definition of the same term in a document incorporated by reference, the meaning or definition
163 assigned to that term in this document shall govern.

164 While particular examples of the present invention have been illustrated and described, it would
165 be obvious to those skilled in the art that various other changes and modifications can be made
166 without departing from the spirit and scope of the invention. It is therefore intended to cover in
167 the appended claims all such changes and modifications that are within the scope of this
168 invention.

CLAIMS

Having thus described in various embodiments of the invention, what is claimed as new and desired to be protected by Letters Patent includes the following:

1. An anti-perspirant and deodorant composition comprising:
 - a. propellant mixture that further includes 65.4356% w/w of isobutane, 16.4000% w/w of propane, 0.1640% w/w of butane,
 - b. 8.2000% w/w of cyclopentasiloxane that has hair conditioning, skin conditioning, emollient, and solvent properties;
 - c. 3.4960% w/w of caprylic/capric triglyceride that has fragrance, skin conditioning, perfuming properties;
 - d. 0.2920% w/w of stearylalkonium hectorite that has gel forming and viscosity controlling properties; 0.2120% w/w of propylene carbonate that has solvent and viscosity controlling properties;
 - e. 2.0000% w/w of c12-15 alkyl benzoate that has antimicrobial, emollient and skin conditioning properties;
 - f. 0.2000% w/w of parfum that has deodorant, masking and perfuming properties;
 - g. 0.0023% w/w of silver lactate that has deodorant properties;
 - h. 0.0023% w/w of lactic acid that has buffering, humectant, and skin conditioning properties;
 - i. 0.4955% w/w of aqua that act as solvent;
 - j. 1.7400% w/w of zein starch that has abrasive, absorbent, anticaking, skin protecting, and viscosity controlling properties, and 0.2600 of aqua that acts as solvent;
 - k. 0.1000% w/w of menthyl ethylamido oxalate that has skin conditioning properties;and

1. 1.0000% w/w of argania spinosa kernel oil that further has emollient and skin conditioning properties.
2. The anti-perspirant and deodorant composition of claim 1, wherein the composition is used on intimate area of human body.
3. The anti-perspirant and deodorant composition of claim 1, wherein the propellant mixture is purified and deodorized using hydrogenation and separation procedure.

INTERNATIONAL SEARCH REPORT

International application No PCT/IB2024/000107

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K8/04 A61K8/26 A61K8/37 A61K8/49 A61K8/58
 A61Q15/00

ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
A61K A61Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO- Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE GNPD [Online] MINTEL; 7 February 2023 (2023-02-07), anonymous: "Feminine Spray", XP093164371, Database accession no. 10558284 *"Product Description" on the first page* *"Ingredients" on the second page*</p> <p style="text-align: center;">----- -/--</p>	1 - 3

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search 26 June 2024	Date of mailing of the international search report 08/07/2024
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center;">Gerber, Myriam</p>
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2024/000107

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 2022/122140 A1 (SYMRISE AG [DE]) 16 June 2022 (2022-06-16) paragraph [0382]; table 23 paragraph [0383]; table 24 paragraph [0388]; table 29 paragraph [0400]; table 40 paragraph [0157] paragraphs [0239], [0240] paragraphs [0373] - [0380]; tables 17-22 paragraphs [0384] - [0387], [0390]; tables 25-28, 30, 31 -----</p>	1-3
Y	<p>US 2015/118172 A1 (RUDOLPH THOMAS [DE] ET AL) 30 April 2015 (2015-04-30) example 8 -----</p>	1-3
Y	<p>US 2021/268035 A1 (RY{HACEK OVER }ÁVKA PETR [CZ] ET AL) 2 September 2021 (2021-09-02) paragraphs [0027], [0029]; claim 14 claims 19, 20 paragraph [0033] paragraph [0035] -----</p>	1-3
Y	<p>US 2022/401354 A1 (MACKTOOM RIMSHA [US] ET AL) 22 December 2022 (2022-12-22) claims 1, 4, 7-9, 15-17 examples; tables 1, 2 -----</p>	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2024/000107

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2022122140 A1	16-06-2022	CN 116634990 A	22-08-2023
		EP 4110276 A1	04-01-2023
		JP 2023552848 A	19-12-2023
		KR 20230117743 A	09-08-2023
		US 2023338250 A1	26-10-2023
		WO 2022122140 A1	16-06-2022
		WO 2022122935 A1	16-06-2022

US 2015118172 A1	30-04-2015	CN 104271109 A	07-01-2015
		EP 2841051 A1	04-03-2015
		JP 2015521161 A	27-07-2015
		RU 2014147075 A	10-06-2016
		US 2015118172 A1	30-04-2015
		WO 2013159865 A1	31-10-2013

US 2021268035 A1	02-09-2021	EP 3871653 A1	01-09-2021
		US 2021268035 A1	02-09-2021

US 2022401354 A1	22-12-2022	AU 2020382526 A1	07-04-2022
		EP 4058154 A1	21-09-2022
		US 2022401354 A1	22-12-2022
		WO 2021096638 A1	20-05-2021
